Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

RANKL regulates male reproductive function.

Tytuł:
RANKL regulates male reproductive function.
Autorzy:
Blomberg Jensen M; Group of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. .; Division of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA. .
Andreassen CH; Group of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Jørgensen A; Department of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Nielsen JE; Department of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Juel Mortensen L; Group of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Division of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.
Boisen IM; Group of Skeletal, Mineral and Gonadal Endocrinology, Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Division of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.
Schwarz P; Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Toppari J; Institute of Biomedicine, Research Centre for Integrated Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, and Department of Pediatrics, Turku University Hospital, Turku, Finland.
Baron R; Division of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.
Lanske B; Division of Bone and Mineral Research, HSDM/HMS, Harvard University, Boston, MA, USA.
Juul A; Department of Growth and Reproduction and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Źródło:
Nature communications [Nat Commun] 2021 Apr 23; Vol. 12 (1), pp. 2450. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [London] : Nature Pub. Group
MeSH Terms:
Fertility/*physiology
RANK Ligand/*metabolism
Semen Analysis/*methods
Sertoli Cells/*metabolism
Spermatozoa/*metabolism
Animals ; Anti-Mullerian Hormone/blood ; Anti-Mullerian Hormone/metabolism ; Denosumab/pharmacology ; Fertility/drug effects ; Humans ; Inhibins/antagonists & inhibitors ; Inhibins/blood ; Inhibins/metabolism ; Male ; Mice, Inbred C57BL ; Mice, Knockout ; Mice, Transgenic ; Osteoprotegerin/pharmacology ; RANK Ligand/antagonists & inhibitors ; RANK Ligand/genetics ; Semen/drug effects ; Semen/metabolism ; Sertoli Cells/drug effects ; Sperm Count ; Spermatozoa/cytology ; Spermatozoa/drug effects
References:
Hum Reprod. 2007 Jun;22(6):1506-12. (PMID: 17376819)
Neoplasia. 2012 Oct;14(10):952-63. (PMID: 23097629)
Oncotarget. 2014 Aug 30;5(16):6647-53. (PMID: 25138051)
J Cell Physiol. 2008 Aug;216(2):536-42. (PMID: 18338379)
FASEB J. 2020 Sep;34(9):12436-12449. (PMID: 32729975)
Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):271-85. (PMID: 21397198)
J Clin Endocrinol Metab. 2018 Mar 1;103(3):870-881. (PMID: 29126319)
Bone. 2019 Jun;123:103-114. (PMID: 30914274)
J Bone Miner Res. 2001 Feb;16(2):348-60. (PMID: 11204435)
J Bone Miner Res. 2009 Feb;24(2):182-95. (PMID: 19016581)
Cell. 1997 Apr 18;89(2):309-19. (PMID: 9108485)
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7082-7. (PMID: 18460605)
Curr Opin Investig Drugs. 2007 Apr;8(4):299-303. (PMID: 17458179)
Apoptosis. 2006 Dec;11(12):2237-50. (PMID: 17051329)
Br J Clin Pharmacol. 2016 Feb;81(2):362-9. (PMID: 26447647)
Nat Med. 2013 Mar;19(3):358-63. (PMID: 23396210)
Horm Res. 2009;71(5):285-9. (PMID: 19339793)
Arthritis Res Ther. 2008;10(1):R2. (PMID: 18182105)
J Exp Med. 1998 Sep 7;188(5):997-1001. (PMID: 9730902)
Endocr Rev. 2008 Apr;29(2):155-92. (PMID: 18057140)
Biologics. 2008 Dec;2(4):645-53. (PMID: 19707445)
Endocrinology. 2001 Dec;142(12):5050-5. (PMID: 11713196)
N Engl J Med. 2009 Aug 20;361(8):756-65. (PMID: 19671655)
Cell. 1998 Apr 17;93(2):165-76. (PMID: 9568710)
Hum Reprod. 2011 Jun;26(6):1307-17. (PMID: 21427118)
J Clin Invest. 2020 Jun 1;130(6):3329. (PMID: 32478683)
Hum Reprod Update. 2004 Jul-Aug;10(4):317-26. (PMID: 15192057)
J Cell Physiol. 2008 Nov;217(2):511-7. (PMID: 18636555)
Mol Cell Endocrinol. 2006 Jul 25;254-255:84-90. (PMID: 16730882)
Nat Commun. 2018 Jul 25;9(1):2909. (PMID: 30046091)
J Steroid Biochem Mol Biol. 2017 Oct;173:215-222. (PMID: 27693423)
Cold Spring Harb Perspect Med. 2018 Jan 2;8(1):. (PMID: 28710257)
Ther Clin Risk Manag. 2012;8:295-306. (PMID: 22767993)
PLoS One. 2014 Apr 15;9(4):e93926. (PMID: 24736722)
Nature. 2018 Sep;561(7722):195-200. (PMID: 30185903)
Lancet. 1972 Sep 9;2(7776):516-7. (PMID: 4115573)
Physiol Rev. 2016 Jan;96(1):55-97. (PMID: 26582516)
Hum Reprod Update. 2002 Mar-Apr;8(2):183-98. (PMID: 12099633)
Hum Reprod. 2006 Jul;21(7):1705-19. (PMID: 16571642)
J Clin Endocrinol Metab. 2004 Jul;89(7):3161-7. (PMID: 15240588)
J Clin Endocrinol Metab. 2017 Mar 1;102(3):950-961. (PMID: 27977320)
Adv Exp Med Biol. 2012;763:237-59. (PMID: 23397628)
Substance Nomenclature:
0 (Osteoprotegerin)
0 (RANK Ligand)
0 (inhibin B)
4EQZ6YO2HI (Denosumab)
57285-09-3 (Inhibins)
80497-65-0 (Anti-Mullerian Hormone)
Entry Date(s):
Date Created: 20210424 Date Completed: 20210510 Latest Revision: 20210513
Update Code:
20240104
PubMed Central ID:
PMC8065035
DOI:
10.1038/s41467-021-22734-8
PMID:
33893301
Czasopismo naukowe
Infertile men have few treatment options. Here, we demonstrate that the transmembrane receptor activator of NF-kB ligand (RANKL) signaling system is active in mouse and human testis. RANKL is highly expressed in Sertoli cells and signals through RANK, expressed in most germ cells, whereas the RANKL-inhibitor osteoprotegerin (OPG) is expressed in germ and peritubular cells. OPG treatment increases wild-type mouse sperm counts, and mice with global or Sertoli-specific genetic suppression of Rankl have increased male fertility and sperm counts. Moreover, RANKL levels in seminal fluid are high and distinguishes normal from infertile men with higher specificity than total sperm count. In infertile men, one dose of Denosumab decreases RANKL seminal fluid concentration and increases serum Inhibin-B and anti-Müllerian-hormone levels, but semen quality only in a subgroup. This translational study suggests that RANKL is a regulator of male reproductive function, however, predictive biomarkers for treatment-outcome requires further investigation in placebo-controlled studies.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies